AHMEDABAD, India I April 19, 2013 I With a view to make Non-Hodgkin’s Lymphoma (NHL) treatment cost-effective, Intas Pharmaceuticals Limited has successfully launched “Mabtas” in India. Mabtas is a biosimilar version of Rituximab, competent in treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. Such diseases include many forms of lymphoma, leukemia, and transplant rejection, autoimmune disorders such as Rheumatoid Arthritis, Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA). Mabtas may be used alone or in combination with other chemotherapy medicines to treat Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
SOURCE: Intas Pharmaceuticals
Post Views: 190
AHMEDABAD, India I April 19, 2013 I With a view to make Non-Hodgkin’s Lymphoma (NHL) treatment cost-effective, Intas Pharmaceuticals Limited has successfully launched “Mabtas” in India. Mabtas is a biosimilar version of Rituximab, competent in treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. Such diseases include many forms of lymphoma, leukemia, and transplant rejection, autoimmune disorders such as Rheumatoid Arthritis, Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA). Mabtas may be used alone or in combination with other chemotherapy medicines to treat Non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
SOURCE: Intas Pharmaceuticals
Post Views: 190
